Those determined to outshine the market strategically focus on the selection of individual stocks. Well-chosen stocks have the potential to substantially boost your wealth.
Tarsus Pharmaceuticals Inc (NASDAQ: TARS) closed the day trading at $51.36 up 2.58% from the previous closing price of $50.07. In other words, the price has increased by $2.58 from its previous closing price. On the day, 0.61 million shares were traded. TARS stock price reached its highest trading level at $51.42 during the session, while it also had its lowest trading level at $49.54.
Ratios:
For a better understanding of TARS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.21 and its Current Ratio is at 5.26. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.22.
On November 20, 2023, Goldman started tracking the stock assigning a Neutral rating and target price of $19.Goldman initiated its Neutral rating on November 20, 2023, with a $19 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 11 ’25 when Azamian Bobak R. bought 6,000 shares for $50.00 per share.
Farrow Jeffrey S sold 13,608 shares of TARS for $550,035 on Jun 17 ’25. The insider now owns 36,704 shares after completing the transaction at $40.42 per share. On Jun 17 ’25, another insider, Farrow Jeffrey S, who serves as the Officer of the company, bought 13,608 shares for $40.42 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TARS now has a Market Capitalization of 2168116224 and an Enterprise Value of 1859419520. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.34 while its Price-to-Book (P/B) ratio in mrq is 6.52. Its current Enterprise Value per Revenue stands at 6.292 whereas that against EBITDA is -19.285.
Stock Price History:
The Beta on a monthly basis for TARS is 0.80, which has changed by 0.9264816 over the last 52 weeks, in comparison to a change of 0.18157876 over the same period for the S&P500. Over the past 52 weeks, TARS has reached a high of $57.28, while it has fallen to a 52-week low of $24.95. The 50-Day Moving Average of the stock is 22.48%, while the 200-Day Moving Average is calculated to be 9.69%.
Shares Statistics:
Over the past 3-months, TARS traded about 637.03K shares per day on average, while over the past 10 days, TARS traded about 799700 shares per day. A total of 42.21M shares are outstanding, with a floating share count of 38.44M. Insiders hold about 8.95% of the company’s shares, while institutions hold 101.56% stake in the company. Shares short for TARS as of 1753920000 were 8136900 with a Short Ratio of 12.77, compared to 1751241600 on 8856844. Therefore, it implies a Short% of Shares Outstanding of 8136900 and a Short% of Float of 19.93.
Earnings Estimates
Current recommendations for the stock of the company come from 4.0 analysts. The consensus estimate for the next quarter is -$0.07, with high estimates of $0.02 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$1.46 and -$1.56 for the fiscal current year, implying an average EPS of -$1.52. EPS for the following year is $0.16, with 3.0 analysts recommending between $1.39 and -$2.15.
Revenue Estimates
5 analysts predict $110.25M in revenue for the current quarter. It ranges from a high estimate of $118.92M to a low estimate of $92.87M. As of the current estimate, Tarsus Pharmaceuticals Inc’s year-ago sales were $48.12MFor the next quarter, 5 analysts are estimating revenue of $127.42M. There is a high estimate of $137.26M for the next quarter, whereas the lowest estimate is $100.32M.
A total of 7 analysts have provided revenue estimates for TARS’s current fiscal year. The highest revenue estimate was $437.18M, while the lowest revenue estimate was $374.18M, resulting in an average revenue estimate of $416.42M. In the same quarter a year ago, actual revenue was $182.95MBased on 6 analysts’ estimates, the company’s revenue will be $600.01M in the next fiscal year. The high estimate is $715.08M and the low estimate is $464.91M.
